- Nachrichtendetail
-
11.07.2024 14:00:31 - dpa-AFX: EQS-News: Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational (english)
Rentschler Biopharma Announces New State-of-the-Art Production Line in
Massachusetts is Fully Operational
EQS-News: Rentschler Biopharma SE / Key word(s): Expansion
Rentschler Biopharma Announces New State-of-the-Art Production Line in
Massachusetts is Fully Operational
11.07.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Rentschler Biopharma Announces New State-of-the-Art Production Line in
Massachusetts is Fully Operational
* Largest expansion in company's 150+-year history opens
Laupheim, Germany and Milford (MA), USA, July 11, 2024 - Rentschler
Biopharma SE, a leading global contract development and manufacturing
organization (CDMO) for biopharmaceuticals, including advanced therapy
medicinal products (ATMPs), today announced that the company's new
state-of-the-art production line, formerly known as the Rentschler Biopharma
Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully
operational. The company has a major project underway at the new line, with
several additional projects in the pipeline, and continues to welcome new
projects and clients.
The new production line is the largest investment in Rentschler Biopharma's
more than 150-year history. The groundbreaking took place in August 2021,
during the COVID-19 pandemic, and the first engineering run of a 2,000L
batch has been recently completed. With this, the line is now fully up and
running. The multi-product facility, which doubles Rentschler Biopharma's
global cGMP capacity, is focusing mainly on commercial production of highly
complex molecules. The original Milford site went from a single-product
commercial facility to producing multiple products in an up to 500L
bioreactor setup. The new production line has added 22,000 square feet of
manufacturing cleanroom space and houses four new 2,000L single-use
bioreactors, bringing the total of production lines at the site up to three.
Benedikt von Braunmühl, CEO of Rentschler Biopharma SE, commented: "As a
fifth-generation, family-owned company, we stand at the forefront of
manufacturing innovative therapies for patients with serious and rare
diseases worldwide. The completion of our new, state-of-the-art production
line is an important milestone for our company and emphasizes Rentschler
Biopharma's strong capabilities in the U.S. Our clients are our partners,
and we are working with them to empower tomorrow's therapies today. Indeed,
in 2023, Rentschler Biopharma was proud to contribute to nearly 25% of the
biopharmaceuticals approved by the U.S. FDA. I would like to thank our teams
on both sides of the Atlantic who worked tirelessly together to get this
important facility online."
Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S.
noted: "Our new line is vital to growing our business and effectively
serving the U.S. market, and I am excited about bringing in new clients as
well as expanding our support of existing ones with a reliability they can
trust.
I also would like to extend my gratitude to the entire team for their strong
support in getting this important new production line up and running. We are
embarking on a new stage in our long and successful history and are poised
to tackle the most complex challenges in biopharmaceutical development and
manufacturing. In light of evolving industry legislation, we remain
committed to supporting our clients responsibly and contributing positively
to both national interests and global health advancements."
Rentschler Biopharma acquired the Milford site in 2019. Since then, the
company has transformed the facility into a multi-product manufacturing
site, expanding it from 93,000 square feet to 138,000 square feet in total.
Earlier this year, the company received the Gold Award for the Central
Massachusetts region in the 20th Annual Team Massachusetts Economic Impact
Awards for its significant contributions to job growth, facility expansion,
investment, and community engagement.
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing
organization (CDMO) focused exclusively on client projects. The company
offers process development and manufacturing of biopharmaceuticals,
including adeno-associated virus (AAV) gene therapies, as well as related
consulting activities, project management and regulatory support. Rentschler
Biopharma's high quality is proven by its long-standing experience and
excellence as a solution partner for its clients. A high-level quality
management system, a well-established operational excellence philosophy and
advanced technologies ensure product quality and productivity at each
development and manufacturing step. Rentschler Biopharma is a family-owned
company with about 1,400 employees, headquartered in Laupheim, Germany, with
a second site in Milford, MA, USA. A third site, located in Stevenage, UK,
is dedicated to advanced therapies. In 2024, the company joined the United
Nations Global Compact, emphasizing Rentschler Biopharma's focus on
sustainability. For further information about the company, please visit
www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn.
Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Head of Communications
Phone: +49-7392-701-874
communications@rentschler-biopharma.com
Media inquiries:
1. mailto:rentschler@mc-services.eu
For high-resolution images, please contact
communications@rentschler-biopharma.com.
---------------------------------------------------------------------------
11.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
1943711 11.07.2024 CET/CEST
Massachusetts is Fully Operational
EQS-News: Rentschler Biopharma SE / Key word(s): Expansion
Rentschler Biopharma Announces New State-of-the-Art Production Line in
Massachusetts is Fully Operational
11.07.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Rentschler Biopharma Announces New State-of-the-Art Production Line in
Massachusetts is Fully Operational
* Largest expansion in company's 150+-year history opens
* Major client project already underway; new clients actively being
onboarded
Laupheim, Germany and Milford (MA), USA, July 11, 2024 - Rentschler
Biopharma SE, a leading global contract development and manufacturing
organization (CDMO) for biopharmaceuticals, including advanced therapy
medicinal products (ATMPs), today announced that the company's new
state-of-the-art production line, formerly known as the Rentschler Biopharma
Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully
operational. The company has a major project underway at the new line, with
several additional projects in the pipeline, and continues to welcome new
projects and clients.
The new production line is the largest investment in Rentschler Biopharma's
more than 150-year history. The groundbreaking took place in August 2021,
during the COVID-19 pandemic, and the first engineering run of a 2,000L
batch has been recently completed. With this, the line is now fully up and
running. The multi-product facility, which doubles Rentschler Biopharma's
global cGMP capacity, is focusing mainly on commercial production of highly
complex molecules. The original Milford site went from a single-product
commercial facility to producing multiple products in an up to 500L
bioreactor setup. The new production line has added 22,000 square feet of
manufacturing cleanroom space and houses four new 2,000L single-use
bioreactors, bringing the total of production lines at the site up to three.
Benedikt von Braunmühl, CEO of Rentschler Biopharma SE, commented: "As a
fifth-generation, family-owned company, we stand at the forefront of
manufacturing innovative therapies for patients with serious and rare
diseases worldwide. The completion of our new, state-of-the-art production
line is an important milestone for our company and emphasizes Rentschler
Biopharma's strong capabilities in the U.S. Our clients are our partners,
and we are working with them to empower tomorrow's therapies today. Indeed,
in 2023, Rentschler Biopharma was proud to contribute to nearly 25% of the
biopharmaceuticals approved by the U.S. FDA. I would like to thank our teams
on both sides of the Atlantic who worked tirelessly together to get this
important facility online."
Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S.
noted: "Our new line is vital to growing our business and effectively
serving the U.S. market, and I am excited about bringing in new clients as
well as expanding our support of existing ones with a reliability they can
trust.
I also would like to extend my gratitude to the entire team for their strong
support in getting this important new production line up and running. We are
embarking on a new stage in our long and successful history and are poised
to tackle the most complex challenges in biopharmaceutical development and
manufacturing. In light of evolving industry legislation, we remain
committed to supporting our clients responsibly and contributing positively
to both national interests and global health advancements."
Rentschler Biopharma acquired the Milford site in 2019. Since then, the
company has transformed the facility into a multi-product manufacturing
site, expanding it from 93,000 square feet to 138,000 square feet in total.
Earlier this year, the company received the Gold Award for the Central
Massachusetts region in the 20th Annual Team Massachusetts Economic Impact
Awards for its significant contributions to job growth, facility expansion,
investment, and community engagement.
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing
organization (CDMO) focused exclusively on client projects. The company
offers process development and manufacturing of biopharmaceuticals,
including adeno-associated virus (AAV) gene therapies, as well as related
consulting activities, project management and regulatory support. Rentschler
Biopharma's high quality is proven by its long-standing experience and
excellence as a solution partner for its clients. A high-level quality
management system, a well-established operational excellence philosophy and
advanced technologies ensure product quality and productivity at each
development and manufacturing step. Rentschler Biopharma is a family-owned
company with about 1,400 employees, headquartered in Laupheim, Germany, with
a second site in Milford, MA, USA. A third site, located in Stevenage, UK,
is dedicated to advanced therapies. In 2024, the company joined the United
Nations Global Compact, emphasizing Rentschler Biopharma's focus on
sustainability. For further information about the company, please visit
www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn.
Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Head of Communications
Phone: +49-7392-701-874
communications@rentschler-biopharma.com
Media inquiries:
MC Services AG U.S.
Eva Bauer Laurie Doyle
Phone: +49-89-210228-0 Phone: +1-339-832-0752
(1)rentschler@mc-services.eu
1. mailto:rentschler@mc-services.eu
For high-resolution images, please contact
communications@rentschler-biopharma.com.
---------------------------------------------------------------------------
11.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
1943711 11.07.2024 CET/CEST
